ArticleFrontiers in microbiology2017
Rifabutin Resistance Associated with Double Mutations in
Article in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.The Journal of antimicrobial chemotherapy · 2018Pooled it
- Article
- Metagenomic identification of pathogens and antimicrobial-resistant genes in bacterial positive blood cultures by nanopore sequencing.Frontiers in cellular and infection microbiology · 2023Article
- Development and Assessment of a Novel Whole-Gene-Based Targeted Next-Generation Sequencing Assay for Detecting the Susceptibility of Mycobacterium tuberculosis to 14 Drugs.Microbiology spectrum · 2022Article
- Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with DisputedMicrobiology spectrum · 2022Article
- Characterization of Genetic Variants Associated with Rifampicin Resistance Level inInfection and drug resistance · 2022Article
- Dependence of Xpert MTB/RIF Accuracy for Detecting Rifampin Resistance in Bronchoalveolar Lavage Fluid on Bacterial Load: A Retrospective Study in Beijing, China.Infection and drug resistance · 2021Article
- In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms.The Journal of antimicrobial chemotherapy · 2020Article
- Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China.BMC infectious diseases · 2019Article
- Global access of rifabutin for the treatment of tuberculosis - why should we prioritize this?Journal of the International AIDS Society · 2019Article
- Article
- Evolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs.Antimicrobial agents and chemotherapy · 2019Article
- A 10-Year Comparative Analysis Shows that Increasing Prevalence of Rifampin-Resistant Mycobacterium tuberculosis in China Is Associated with the Transmission of Strains Harboring Compensatory Mutations.Antimicrobial agents and chemotherapy · 2018Article
- Commentary: Rifabutin Resistance Associated with Double Mutations inFrontiers in microbiology · 2017Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to investigate the cross-resistance between rifampin (RIF) and rifabutin (RFB) among clinical
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.